Related Experiment Video
Updated: Feb 14, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Identification of FAM173B as a protein methyltransferase promoting chronic pain
Hanneke L D M Willemen1, Annemieke Kavelaars2, Judith Prado3
1Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Abstract:
Chronic pain is a debilitating problem, and insights in the neurobiology of chronic pain are needed for the development of novel pain therapies. A genome-wide association study implicated the 5p15.2 region in chronic widespread pain. This region includes the coding region for FAM173B, a functionally uncharacterized protein. We demonstrate here that FAM173B is a mitochondrial lysine methyltransferase that promotes chronic pain. Knockdown and sensory neuron overexpression strategies showed that FAM173B is involved in persistent inflammatory and neuropathic pain via a pathway dependent on its methyltransferase activity. FAM173B methyltransferase activity in sensory neurons hyperpolarized mitochondria and promoted macrophage/microglia activation through a reactive oxygen species-dependent pathway. In summary, we uncover a role for methyltransferase activity of FAM173B in the neurobiology of pain. These results also highlight FAM173B methyltransferase activity as a potential therapeutic target to treat debilitating chronic pain conditions.
Related Concept Videos
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Pain
Anaphase Promoting Complex
Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

